Galectin Therapeutics Inc.
GALT
$4.05
-$0.09-2.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.85M | 1.85M | 1.43M | 1.59M | 1.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.98M | 4.08M | 3.37M | 4.20M | 4.63M |
| Operating Income | -3.98M | -4.08M | -3.37M | -4.20M | -4.63M |
| Income Before Tax | -9.11M | -5.05M | -5.50M | -8.18M | -7.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.11M | -5.05M | -5.50M | -8.18M | -7.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.11M | -5.05M | -5.50M | -8.18M | -7.52M |
| EBIT | -3.98M | -4.08M | -3.37M | -4.20M | -4.63M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.14 | -0.08 | -0.09 | -0.13 | -0.12 |
| Normalized Basic EPS | -0.09 | -0.05 | -0.05 | -0.08 | -0.07 |
| EPS Diluted | -0.14 | -0.08 | -0.09 | -0.13 | -0.12 |
| Normalized Diluted EPS | -0.09 | -0.05 | -0.05 | -0.08 | -0.07 |
| Average Basic Shares Outstanding | 65.88M | 65.78M | 64.74M | 64.21M | 63.45M |
| Average Diluted Shares Outstanding | 65.88M | 65.78M | 64.74M | 64.21M | 63.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |